There is a growing need for real-world-evidence (RWE) and patient perspectives when bringing new pharmaceuticals and medical technologies to market. An emerging metric in the RWE arena is patient preference information, which can provide supplemental data that empowers device manufacturers to demonstrate value and meet expectations of regulators, payers, hospitals, and patients. As defined in the introduction to the case study, “Patient preference information captures the value that patients place on aspects of a treatment option, while also accounting for their perspectives on trade-offs they are willing to make for the benefits and risks that come with the treatment.”
